Paige.ai

About Paige.ai

Financials

Dated, source-cited figures. Estimates are marked.

Products by Paige.ai

All products by Paige.ai reviewed by our AI panel of experts.

PaigeAI Healthcare

AI-powered pathology intelligence for cancer diagnostics

Free7.9/10

How Our Review Panel Scores Paige.ai

Six independent reviewer personalities assessed Paige.ai's product on their own terms. They disagreed by 2.4 points — The Finance Lead was the hardest to convince, The Domain Strategist the most positive.

Averaged across 1 reviewed product in our catalog. Scores are out of 10.

Competitive Landscape

Who Paige.ai competes with, and how they differ.

PathAI7.9/10

PathAI pairs its AI platform with pathology lab services (via its Poplar Healthcare acquisition) and focuses heavily on pharma biomarker and companion-diagnostic development, while Paige built FDA-authorized products (Paige Prostate, Paige Breast) aimed directly at clinical diagnostic use in hospital labs.

1 product reviewed on TopReviewed

Lunit Inc.7.9/10

Lunit's AI portfolio is radiology-first (Lunit INSIGHT for chest X-ray and mammography screening), with its newer Lunit SCOPE pathology line a smaller addition versus Paige's pathology-only focus and its longer track record of FDA-cleared cancer-detection products.

1 product reviewed on TopReviewed

P

Proscia

Proscia sells a cloud-based digital pathology image-management and AI platform (Concentriq) to labs and pharma customers, competing with Paige on pathology workflow infrastructure rather than matching Paige's FDA-authorized diagnostic AI models.

Company Timeline

Key milestones in Paige.ai's history, with sources.

1. Aug 22, 2025Acquisition

   Acquired by Tempus AI for $81.25M

   Tempus AI (NASDAQ: TEM) acquired Paige for $81.25 million, paid primarily in stock, gaining almost 7 million digitized pathology slides and clinical/molecular data spanning 45 countries to accelerate its oncology foundation model.

   medtechdive.com
2. Aug 8, 2024Launch

   Virchow2 and Virchow2G foundation models released

   Paige and Microsoft unveiled Virchow2 and Virchow2G, the second generation of their million-slide pathology foundation models, adding greater data diversity and depth for cancer detection.

   paige.ai
3. September 2023Partnership

   Microsoft Research partnership to build pathology foundation model

   Paige announced a collaboration with Microsoft Research to build what the companies called the world's largest image-based AI foundation model for digital pathology and oncology, later released as Virchow.

   paige.ai
4. Sep 21, 2021Milestone

   FDA authorizes Paige Prostate -- first AI pathology product cleared

   The FDA granted De Novo marketing authorization for Paige Prostate, the first AI-based software authorized to help pathologists detect prostate cancer in digitized biopsy slides; a clinical study of 16 pathologists on 527 slides showed a 7.3-point accuracy improvement.

   mobihealthnews.com
5. January 2021Funding

   Series C -- $100M initial close

   Paige raised a $100 million Series C round co-led by Casdin Capital and Johnson & Johnson Innovation - JJDC; the round grew to over $125 million after a final tranche led by KKR Health Care Strategic Growth Fund closed in March 2021.

   mobihealthnews.com
6. Dec 8, 2020Milestone

   CE Mark for Paige Prostate and Paige Breast AI

   Paige received CE Marks for its AI-based prostate cancer grading/quantification and breast cancer detection software, clearing the products for use in labs and hospitals across the European Economic Area, Switzerland and the UK.

   businesswire.com
7. Jul 14, 2020Funding

   Series B -- $70M

   Paige raised a $70 million Series B round to advance its AI-based computational pathology products for cancer diagnosis.

   aibusiness.com
8. Feb 18, 2019Milestone

   Leo Grady named CEO

   Paige named med-tech executive Leo Grady, previously of HeartFlow, as its first CEO to lead commercialization of its AI pathology products.

   wsj.com
9. 2019Milestone

   FDA grants Breakthrough Device designation

   Paige's AI pathology software received FDA Breakthrough Device designation in 2019, its first US regulatory recognition ahead of the 2021 De Novo authorization for Paige Prostate.

   mobihealthnews.com
10. Feb 5, 2018Launch

    Public launch to apply AI to cancer pathology

    Paige.AI launched publicly, announcing its mission to bring AI-based computational pathology tools to cancer diagnosis and treatment, built on IP licensed from Memorial Sloan Kettering.

    businesswire.com
11. 2017Founded

    Founded as a Memorial Sloan Kettering spinout

    Paige (originally Paige.AI) was founded in 2017 by Thomas Fuchs, Christopher Selby and David Klimstra -- chair of pathology at Memorial Sloan Kettering Cancer Center -- after MSK licensed its computational pathology intellectual property to the new company.

    mskcc.org